Pfizer's Challenge On Generic Marketing Exclusivity Waivers Rejected By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Waiver and relinquishment of generic marketing exclusivity are permitted under the FD&C Act and promote marketplace competition, FDA says. Pfizer asserted that treating 180-day exclusivity as an "alienable" asset would encourage the filing of speculative ANDAs.
You may also be interested in...
FDA Signs Off On "Authorized" Generics; Deals Are Pro-Competitive, Agency Says
FDA is not empowered to directly regulate the timing for marketing of previously approved drug products, the agency says in response to citizen petitions from Mylan and Teva. The two companies wanted FDA to prohibit the marketing of authorized generics during a first ANDA filer's 180-day exclusivity period.
FDA Signs Off On "Authorized" Generics; Deals Are Pro-Competitive, Agency Says
FDA is not empowered to directly regulate the timing for marketing of previously approved drug products, the agency says in response to citizen petitions from Mylan and Teva. The two companies wanted FDA to prohibit the marketing of authorized generics during a first ANDA filer's 180-day exclusivity period.
Teva, Ivax Move Closer To Marketing Generic Gabapentin; Neurontin Litigation Continues
Ivax receives full ANDA approval for low dose tablet formulations of gabapentin. Teva licenses Alpharma's generic exclusivity for capsule form and higher dose tablets.